Companies Z Factor

Building treatments for alpha-1 antitrypsin deficiency


Z Factor, now acquired by Centessa Pharmaceuticals, is a clinical-stage biotechnology company whose aim is to develop a therapy to put right a common genetic disorder.

A single mistake in the DNA encoding the alpha-1 antitrypsin (A1AT) protein causes liver and lung disease. Z Factor’s lead candidate is a novel compound that enables the Z variant of A1AT to fold correctly relieving the liver and protecting the lungs.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More